40 results about "Neospora species" patented technology

The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1 / MAG1 promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.

The present invention relates to a novel Neospora caninum isolate from Nowra and extracts thereof. The strain is useful in the development of diagnostic assays for the detection of parasites in animals. The present invention also relates to pharmaceutical compositions, using live or killed organisms or extracts thereof, for the treatment and prevention of parasitic infections in animals.

The present invention relates to the serological detection of animals inoculated with Neospora by reacting the test serum with a protein reactive with Neospora. The protein may be a full-length natural or recombinant Neospora or T. gondii bradyzoite fusion protein or a truncated fusion protein or a fragment thereof. The protein can be used in any of a number of assays including enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), Western blot and other suitable forms of immunoassay.

A Neospora caninum vaccine comprising tissue culture grown Neospora and methods of making and using said vaccines. Neospora caninum vaccines described include those containing whole Neospora tachyzoites, extracts of Neospora tachyzoites and protective antigen subunits of Neospora tachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.

The invention provides a neospora caninum specific nest-polymerase chain reaction (PCR), which is used for testing tachyzoite, tissue cyst and oocyst infected with neospora caninum in different animals. The invention also discloses a preparation method of the nest-PCR test kit. The nest-PCR is used for amplifying some specific molecular fragment of a gene of a neospora caninum for diagnosing neosporosis. The invention relates to neospora caninum and a neospora caninum specific gene SEQNo.1 which is screened from an ultramicro-structure suppressed subtractive hybridization library. The gene is the specific to neospora caninum, so amplification of fragments of SEQNo.1 gene in animal tissue and dung by the nest-PCR can be used for molecule detection of neospora caninum and diagnosing acute, chronic and recessive infection with neospora caninum.

A Neospora caninum vaccine comprising tissue culture grown Neospora and methods of making and using said vaccines. Neospora caninum vaccines described include those containing whole Neospora tachyzoites, extracts of Neospora tachyzoites and protective antigen subunits of Neospora tachyzoites. The vaccines of this invention may be in a liquid or lyophilized form.

A vaccine preparation characterized in that Neospora caninum-derived dense granule protein 7 or apical membrane antigen 1 or an immunologically active variant or derivative thereof is included in liposomes each having an oligosaccharide capable of binding to a carbohydrate recognition molecule on the surface of antigen-presenting cells on the surface of the liposome.

The invention provides a vaccine for prevention and control of neosporiasis of cattle as well as a preparation method and an application of the vaccine. The vaccine is a gene adjuvant recombinant adenovirus carrier vaccine, and the nucleotide sequence of a vaccine antigen is encoded as in SEQ.ID.NO.1. A preparation method of the vaccine comprises steps as follows: primers are designed according to open reading frames of an NcSRS 9 gene sequence and an IFN-gamma gene sequence of Neospora caninum, an NcSRS 9 gene and an IFN-gamma gene are amplified and spliced, a pMD18T-NcSRS9-IFN-gamma recombinant clone plasmid is built, a shuttle plasmid pCR259-NcSRS9-IFN-gamma and an expression plasmid H294-NcSRS9-IFN-gamma of a recombinant adenovirus are built, Ad5-NcSRS9-IFN-gamma recombinant adenoviruses are packed with QBI-HEK293 cells through lipidosome mediation and transfection, and amplification and purification are performed to prepare the recombinant adenovirus carrier vaccine.

The invention discloses a Neospora caninum specific PCR detection kit and its preparation method and application, wherein the specific gene sequence of Neospora caninum is SEQ ID NO.1, and the specific gene sequence has five further designed the amplification primers of the specific gene sequence and constructed the Neospora caninum PCR detection kit, which is intended to be applied to the clinical detection and screening of Neospora caninum infection in animals, and can accurately and rapidly diagnose Neospora caninum infection. Caused by the pathogen of female abortion and the investigation of Neospora infection in animal populations.

The invention discloses the medical application of the compound pyrogallol in anti-Neospora canis, and can be made into a novel anti-Neospora caninum drug, and its anti-Neospora effect on neospores is confirmed by two aspects of animal experiments acting on host cells and mouse models Therapeutic effect of worm, can be made into the chemical medicine that suppresses Neospora cell infection and mouse model heart, liver, spleen, lung, kidney, brain tissue infection, has remarkable curative effect; The present invention provides for the treatment of Neospora The new candidate drug target-reactive oxygen species (ROS) and the new drug candidate-pyrogallol lay the foundation for the search for new drugs against neosporosis in the future.

The invention provides a neosporosis rELISA antibody assay kit. The neosporosis recombinant enzyme-linked immunosorbent assay (rELISA) antibody assay kit is characterized in that designing a primer set according to a neospora caninum NcSRS2 gene of the GenBank, introducing the primer set to an enzyme digestion site, removing a signal peptide zone of an NcSRS2 protein, extracting a DNA from Xinjiang cow positive serum, carrying out polymerase chain reaction (PCR) amplification of the DNA to obtain a tNcSRS2 genetic fragment having length of 975bp, cloning the tNcSRS2 genetic fragment into a pMD-18-T carrier, carrying out enzyme digestion and sequencing, further directionally connecting the desired fragment obtained by the previous step to a pGEX-4T-2 expression carrier, transferring the pGEX-4T-2 expression carrier with the desired fragment into escherichia coli, carrying out inducible expression and purification, wherein expressed fusion protein molecular weight is about 62kDa, and carrying out ELISA antigen coating by the expressed fusion protein to obtain the neosporosis rELISA antibody assay kit. A use method of the neosporosis rELISA antibody assay kit comprises the following steps that a coated enzyme label reaction plate is taken out, is subjected to first washing, is enclosed, is subjected to second washing, is added with a sample needing to be detected, is subjected to third washing, is added with a secondary antibody, is subjected to fourth washing, and undergoes a color reaction; and when the color reaction is finished, an OD450 / 630 value of the coated enzyme label reaction plate is read and a result is determined. Compared with a commercial ELISA assay kit, the neosporosis rELISA antibody assay kit has a higher coincidence rate above 95% The neosporosis rELISA antibody assay kit also is suitable for the ELISA of a neospora caninum antibody in ruminant serum and blood plasma.

The invention discloses a sarcocystis fusion antigen, coding gene, indirect ELISA antibody detection kit and application thereof, belonging to the technical field of animal or human disease detection. The sarcocystis fusion antigen of the present invention consists of the partial amino acid sequence (37-118) of the surface antigen SAG3 of Sarcocystis mieni, a flexible peptide of 15 amino acids and the partial amino acid sequence of the surface antigen SAG4 of Sarcocystis cruzi (No. 165‑264) constitutes; this fusion antigen has very strong antigenicity and specificity, can produce effective antigen antibody reaction with S. The positive sera of Toxoplasma gondii and Neospora caninum produce cross-immune reactions, which are ideal detection antigens for detecting antibodies against Sarcocystis micheni and Sarcospora cruzi, and have a good application prospect.

The invention provides a vaccine for prevention and control of neosporiasis of cattle as well as a preparation method and an application of the vaccine. The vaccine is a gene adjuvant recombinant adenovirus carrier vaccine, and the nucleotide sequence of a vaccine antigen is encoded as in SEQ.ID.NO.1. A preparation method of the vaccine comprises steps as follows: primers are designed according to open reading frames of an NcSRS 9 gene sequence and an IFN-gamma gene sequence of Neospora caninum, an NcSRS 9 gene and an IFN-gamma gene are amplified and spliced, a pMD18T-NcSRS9-IFN-gamma recombinant clone plasmid is built, a shuttle plasmid pCR259-NcSRS9-IFN-gamma and an expression plasmid H294-NcSRS9-IFN-gamma of a recombinant adenovirus are built, Ad5-NcSRS9-IFN-gamma recombinant adenoviruses are packed with QBI-HEK293 cells through lipidosome mediation and transfection, and amplification and purification are performed to prepare the recombinant adenovirus carrier vaccine.